A Single Arm Open-label, Phase II Study of Sipuleucel-T with Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Sipuleucel-T (Primary) ; Testosterone cipionate (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 12 Jan 2024 Status changed from not yet recruiting to recruiting.
- 27 Oct 2023 New trial record